Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine
Molecular Oncology, EarlyView.The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu +18 more
wiley +1 more source
Management and safety of same day bilateral intravitreal anti-VEGF injections in a treat-and-extend regimen. [PDF]
BMC OphthalmolPlasencia C, Eschle J, Hatz K.
europepmc +1 more source
Eisenmenger Syndrome in Case of Extended Goldenhar Complex Treated With Heart-Lung Transplantation
, 2022 Cesar A. Keller, Francisco Alvarez
openalex +1 more source
A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression
Molecular Oncology, EarlyView.Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak +8 more
wiley +1 more source
Clinical OphthalmologyIori Wada,1,2 Yuji Oshima,3 Yosuke Fukuda,1 Satomi Shiose,1 Kumiko Kano,1 Keijiro Ishikawa,1 Shintaro Nakao,4 Yoshihiro Kaizu,1,5 Eiichi Hasegawa,1,2 Ram Kannan,6,7 Tatsuro Ishibashi,1 Koh-Hei Sonoda1 1Department of Ophthalmology, Graduate School of ...
Wada I +11 more
doaj
One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration. [PDF]
BMC OphthalmolMenghini M +4 more
europepmc +1 more source
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization. [PDF]
Sci Rep, 2023 Matsumoto H +3 more
europepmc +1 more source